Previous 10 | Next 10 |
Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAV...
2023-11-16 07:17:43 ET More on LAVA Therapeutics Seeking Alpha’s Quant Rating on LAVA Therapeutics Historical earnings data for LAVA Therapeutics Financial information for LAVA Therapeutics For further details see: LAVA Therapeutics GAAP EPS of -$0...
LAVA-1207 in mCRPC continues Phase 1/2a dose escalation study in monotherapy arm and in combination with IL-2 Seagen initiated a Phase 1 study of SGN-EGFRd2 (LAVA-1223) to evaluate the safety and tolerability utilizing the Gammabody ® platform as a monotherapy in advanced EGFR expres...
The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...
LAVA Therapeutics N.V. (LVTX) is expected to report $-0.48 for Q3 2023
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the...
2023-08-22 08:49:15 ET More on LAVA Therapeutics Lava Therapeutics shelves hematology drug over competitive concerns LAVA Therapeutics initiated at buy at Wainwright on Gammabodies to treat cancer Lava Therapeutics begins dosing in phase 1/2a trial of LAVA-1207 to tr...
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8 Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by Seagen Portfolio reprioritization and extension of cas...
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody ® platform of bispecific gamma-delta T cell engagers to transf...
2023-06-16 08:33:21 ET Virgin Galactic ( SPCE ) +42% stock movers today: Virgin Galactic, Coherent and more. VCI Global ( VCIG ) +35% Marks Debut into Artificial Intelligence (“AI”) and Big Data Industries Through Partnership with Fusionex. ...
News, Short Squeeze, Breakout and More Instantly...
LAVA Therapeutics N.V. Company Name:
LVTX Stock Symbol:
NASDAQ Market:
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company")), a cl...
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamm...
2024-03-20 10:20:00 ET March 20, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies are involved in immuno-oncology, ...